Scientific Opinion on the safety of ‘sardine Peptide Product’

EFSA Journal

Volumn 8, Issue 7, 2010, Pages

[No Author Info available]

Author keywords

ACE inhibition; hypertension; ingredient; novel food; peptides; Sardine; Val Tyr dipeptide

Indexed keywords

EID: 85078389689     PISSN: None     EISSN: 18314732     Source Type: Journal    
DOI: 10.2903/j.efsa.2010.1684     Document Type: Article

References (25)

1. Bai JP and Amidon GL, 1992. Structural specificity of mucosal-cell transport and metabolism of peptide drugs: implication for oral peptide drug delivery. Pharmaceutical Research, 9, 969–978.
2. Cushman DW and Cheung HS, 1971, Spectrophotometric assay and properties of the angiotensin-converting enzyme of rabbit lung, Biochemical Pharmacology, 20: 1637–1648.
3. EC (Commission of the European Communities), 1997. Commission Recommendation of 29 July 1997 concerning the scientific aspects and the presentation of information necessary to support applications for the placing on the market of novel foods and novel food ingredients and the preparation of initial assessment reports under Regulation (EC) No 258/97 of the European Parliament and of the Council (97/618/EC). Official Journal of the European Communities, L253:1–36.
4. EC (Commission of the European Communities), 2006a. Commission Regulation (EC) No 1881/2006 of 19 December 2006 setting maximum levels for certain contaminants in foodstuffs. Official Journal of the European Union, L364:5–24.
5. EP (European Parliament and the Council of the European Union), 2003. Directive 2003/89/EC of the European Parliament and of the Council of 10 November 2003 amending Directive 2000/13/EC as regards indication of the ingredients present in foodstuffs. Official Journal of the European Communities 2003, L308:15–18.
6. EP (European Parliament and the Council of the European Union), 2004. Regulation (EC) No 852/2004 of the European Parliament and of the Council of 29 April 2004 on the hygiene of foodstuffs. Official Journal of the European Union 2004, L139:1–54 [& Corrigendas, 47(L226):3–21 & 50(L204):26].
7. Kajimoto O, Osajima K, Matsui T, Matsjumoto K, Osajima Y, Hirata H, Yabune M, Kawasaki T, 2003. Hypotensive effects of food containing peptide derived from sardine muscle hydroyzate, in subjects with high-normal, or hypertension. Journal of Nutritional Food = Kenko Eiyo Shokuhin Kenkyu, 6:65–82 [Engl. Translation].
8. Kajimoto O, Nakagawa S, Kajimoto Y, Takashiba M, Shimano K, 2005a. Evaluation of the safety in excess administration of tea beverage containing peptide derived from sardine muscle hydrolyzate on humans. Yakuri to Chiry$o. Basic Pharmacology & Therapeutics, 33:1113–1125 [Engl. Translation].
9. Kajimoto O, Nakagawa S, Kajimoto Y, Takashiba M, Shimano K, 2005b. Hypotensive effects and safety of tea beverage containing peptide derived from sardine muscle hydrolyzate on high normal blood pressure and mild hypertensive subjects. Yakuri to Chiryo. Basic Pharmacology & Therapeutic, 33:1127–1140 [Engl. Translation].
10. Kawasaki T, Seki E, Osajima K, Yoshida M, Asada K, Matsui T, Osajima Y. Antihypertensive effect of valyl-tyrosine, a short chain peptide derived from sardine muscle hydrolyzate, on mild hypertensive subjects. Journal of Human Hypertension 2000, 14:519–523.
11. Kawasaki T, Jun CJ, Fukushima Y, Kegai K, Seki E, Osajima K, Itoh K, Matsui T, Matsumoto K. Antihypertensive effect and safety evaluation of vegetable drink with peptides derived from sardine protein hydrolysates on mild hypertensive, high-normal and normal blood pressure subjects. Fukuoka Igaku Zasshi = Hukuoka Acta Medica 2002, 93:208–218 [Engl. Translation].
12. Maruyama S and Suzuki H, 1982. A peptide inhibitor of angiotensin I converting enzyme in the tryptic hydrolysate of casein. Agricultural and Biological Chemistry 1982, 46:1393–1394.
13. Matsufuji H, Matsui T, Seki E, Osajima K, Nakashima M, Osajima Y, 1994. Angiotensin I-converting enzyme inhibitory peptides in an alkaline protease hydrolyzate derived from sardine muscle. Bioscience, Biotechnology, and Biochemistry, 58:2244–2245.
14. Matsui T, Matsufuji H, Seki E, Osajima K, Nakashima M, Osajima Y, 1993. Inhibition of angiotensin I-converting enzyme by Bacillus licheniformis alkaline protease hydrolyzates derived from sardine muscle. Bioscience, Biotechnology, and Biochemistry, 57:922–925.
15. Matsui T, Tamaya K, Seki E, Osajima K, Matsumoto K, Kawasaki T, 2002a. Val-Tyr as a natural antihypertensive dipeptide can be absorbed into the human circulatory blood system. Clinical and Experimental Pharmacology & Physiology, 29:204–208.
16. Matsui T, Tamaya K, Seki E, Osajima K, Matsumo K, Kawasaki T, 2002b. Absorption of Val-Tyr with in vitro angiotensin I-converting enzyme inhibitory activity into the circulating blood system of mild hypertensive subjects. Biological & Pharmaceutical Bulletin, 25:1228–1230.
17. Matsui T, Hayashi A, Tamaya K, Matsumoto K, Kawasaki T, Murakami K, Kimoto K-I, 2003. Depressor effect induced by dipeptide, Val-Tyr, in hypertensive transgenic mice, is due, in part, to the suppression of human circulating renin-angiotensin system. Clinical and Experimental Pharmacology & Physiology, 30:262–265.
18. Matsui T, Imamura M, Oka H, Osajima K, Kimoto K-I, Kawasaki T, Matsumoto K, 2004. Tissue distribution of antihypertensive dipeptide, Val-Tyr, after its single oral administration to spontaneously hypertensive rats. Journal of Peptide Science, 10:535–545.
19. Matsui T, Zhu XL, Watanabe K, Tanaka K, Kusano Y, Matsumoto K, 2006. Combined administration of captopril with an antihypertensive Val-Tyr di-peptide to spontaneously hypertensive rats attenuates the blood pressure lowering effect. Life Sciences, 79:2492–2498.
20. Matsutani Chemical Industry, 1999. Japanese Market Information: TOKUHO, Food for Specified Health Use (FOSHU). Matsutani Chemical Industry, Japan. Available at: www.matsutani.com/fibersol2marketinjp.html.
21. MHLW. Food for Specified Health Uses (FOSHU). Ministry of Health, Labor and Welfare (MHLW), Japan; 2007. Available at: www.mhlw.go.jp/english/topics/foodsafety/fhc/02.html.
22. Morishima A, 1992 [unpublished study report]. Single Oral Dose Toxicity Study of Peptide a-1000 in Rats. Jisseiken Co.; [Study No. B9214-1, Nov. 5, 1992].
23. Morishima A, 1993 [unpublished study report]. A 28-Day Repeated Oral Administration Toxicity Study of Peptide a-1000 in Rats. Jisseiken Co.; [Study No. B9214-2, Apr. 6, 1993].
24. Schoenmakers RG, Stehouwer MC, Tukker JJ, 1999. Structure-transport relationship for the intestinal small-peptide carrier: is the carbonyl group of the peptide bond relevant for transport? Pharmaceutical Research, 16:62–68.
25. Yang CY, Dantzig AH, Pidgeon C, 1999. Intestinal peptide transport systems and oral drug availability. Pharmaceutical Research, 16:1331–1343.